"The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing "...
There are no data available on the effects of acute or chronic overdose. However, acute overdosing with Azmacort (triamcinolone acetonide (inhalation aerosol)) Inhalation Aerosol is unlikely in view of the total amount of active ingredient present and the route of administration. The maximum total daily dose (1200 mcg) has been well tolerated when administered as a single dose of 16 consecutive inhalations to adult asthmatics in a controlled clinical trial. Chronic overdosage may result in signs/symptoms of hypercorticoidism. (See PRECAUTIONS.) The risk of candidiasis could also be increased.
Azmacort (triamcinolone acetonide (inhalation aerosol)) Inhalation Aerosol is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.
Hypersensitivity to triamcinolone acetonide or any of the other ingredients in this preparation contraindicates its use.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/13/2016
Additional Azmacort Information
Azmacort - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.